Market capitalization | $1.85b |
Enterprise Value | $1.42b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 17.84 |
P/S ratio (TTM) P/S ratio | 23.30 |
P/B ratio (TTM) P/B ratio | 2.60 |
Revenue growth (TTM) Revenue growth | 70.16% |
Revenue (TTM) Revenue | $79.41m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
16 Analysts have issued a Kymera Therapeutics Inc forecast:
16 Analysts have issued a Kymera Therapeutics Inc forecast:
Dec '23 | |
Current assets | 405 405 |
Fixed assets | 170 170 |
Total Assets | 576 576 |
Dec '23 | |
Equity | 395 395 |
Debt capital | 181 181 |
Total Capital | 576 576 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.
Head office | United States |
CEO | Nello Mainolfi |
Employees | 187 |
Founded | 2015 |
Website | www.kymeratx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.